1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,015 | 0,027 | 18.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Genflow Biosciences PLC: Genflow Completes Dosing Phase of Canine Gene Therapy Trial | 140 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| Di | Genflow Biosciences - Completion of Dosing Phase of Canine Gene Therapy | 1 | RNS | ||
| 11.12. | Genflow Biosciences to attend J.P. Morgan Healthcare Conference | 2 | Investing.com | ||
| 11.12. | Genflow Biosciences nimmt an J.P. Morgan Healthcare Conference teil | 4 | Investing.com Deutsch | ||
| 11.12. | Genflow Biosciences PLC: Genflow to Attend Healthcare Conference | 176 | ACCESS Newswire | Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 11.12. | Genflow Biosciences - Genflow to Attend Healthcare Conference | 2 | RNS | ||
| 31.10. | Genflow Biosciences PLC Announces Total Voting Rights | 229 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
| 31.10. | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 24.10. | Genflow Biosciences PLC Announces Holding(s) in Company | 199 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 22.10. | TRADING UPDATES: Genflow patent progress; Accsys new debt facilities | 2 | Alliance News | ||
| 22.10. | Genflow Biosciences announces second European patent application | 2 | Seeking Alpha | ||
| 22.10. | Genflow Biosciences PLC Announces Second European Patent Application | 240 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 22.10. | Genflow Biosciences - Second European Patent Application | 2 | RNS | ||
| 20.10. | Genflow Biosciences says European patent publication is "step forward" | 2 | Alliance News | ||
| 20.10. | Genflow Biosciences PLC Announces Recognition of Patentability of Claims | 183 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 20.10. | Genflow Biosciences - Recognition of Patentability of Claims | 2 | RNS | ||
| 10.10. | Genflow Biosciences hails data from trial of dog ageing gene therapy | 1 | Alliance News | ||
| 10.10. | Genflow Biosciences PLC Announces Update on Animal Health Program | 243 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 10.10. | Genflow Biosciences - Update on Animal Health Program | 1 | RNS | ||
| 09.10. | Genflow Biosciences PLC Announces Update, Equity Issue and PDMR Notification | 232 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 79,63 | -2,97 % | Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital | ||
| QIAGEN | 38,445 | -0,09 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,14 | +0,37 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 269,26 | +1,28 % | Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer | ||
| APOGEE THERAPEUTICS | 77,35 | +2,41 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,900 | -3,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,010 | -1,10 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,440 | 0,00 % | What's Happening With RXRX Stock? | ||
| MINERALYS THERAPEUTICS | 37,000 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,470 | -3,38 % | Harmony Biosciences partners with Beacon for EEG data in sleep trials | ||
| DAY ONE BIOPHARMACEUTICALS | 9,970 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| ATHIRA PHARMA | 6,740 | 0,00 % | Athira Pharma, Inc.: Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million | Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing... ► Artikel lesen | |
| DISC MEDICINE | 90,44 | +3,37 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 30,730 | 0,00 % | From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen | |
| MAZE THERAPEUTICS | 40,620 | +5,78 % | Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study |
Das Unternehmen GENFLOW BIOSCIENCES PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+5,41 %) liegt der Kurs bei 0,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.